<DOC>
	<DOC>NCT00268840</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy of combination therapy with gemcitabine and docetaxelin in patients with locally advanced or metastatic pancreatic or biliary adenocarcinoma.</brief_summary>
	<brief_title>The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer</brief_title>
	<detailed_description>Try a new drug association on this advanced cancer</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients aged 18 years or older Patients must sign informed consent prior to study entry Patients has Karnofsky performance status of more than 50% No prior chemotherapy Histologically or cytologically confirmed adenocarcinoma of the pancreas, locally advanced or metastatic disease or biliary cancer No previous radiotherapy for locally advanced or metastases. Hematopoietic: WBC &gt; 3000/mm2, Absolute neutrophile count &gt; 1500/mm2, Hemoglobin &gt; 9g/dl, Platelet count &gt; 100 000/mm2 No intracerebral or meningeal metastases Pregnant Fertile patient must use effective contraception No other serious medical condition or illness that would preclude study participation Hepatic: Bilirubin greater than upper limit of normal(ULN) SGOT and SGPT &gt; 3.5 times upper limit of normal(ULN) alkaline phosphatase &gt; 6 times upper limit of normal(ULN) More than 30 days since prior investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Pancreas or biliary cancer</keyword>
</DOC>